News
VeraSci Receives FDA Grant to Support Qualification of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that they have received an FDA grant to conduct further research on the VRFCAT, their proprietary functional capacity assessment. The VRFCAT has recently been accepted...
read moreVeraSci’s Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Accepted into the FDA’s Clinical Outcome Assessment (COA) Qualification Program
VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that their proprietary functional capacity assessment, the VRFCAT has officially been accepted into the FDA’s COA Qualification Program.
read moreVeraSci Continues Growth Strategy with Hire of Hampton Corley as Chief Commercial Officer
VeraSci, a leading provider of innovative scientific and technology services, announced today the hire of Hampton Corley, Chief Commercial Officer, to support growth objectives. As clinical trials grow in scope and complexity, VeraSci provides the scientific and operational clarity needed for optimal trial performance and accelerated drug development.
read moreVeraSci Welcomes William P. Horan, PhD as VP of Clinical Science
VeraSci, a leading provider of innovative scientific and technology services, announced today that William P. Horan, PhD will join the company as Vice President of Clinical Science. In this role, Dr. Horan will use his expertise in cognition, clinical neuroscience,...
read moreLeading Provider of Innovative Scientific and Technology Services Welcomes Mark Skeen, MD as Senior Medical Scientist
VeraSci recently welcomed Mark Skeen, MD as Senior Medical Scientist. In this role Dr. Skeen will provide disease state expertise for a broad range of neurologic diseases as well as the perspective of the clinician conducting clinical trials. As part of his role at...
read moreSignificant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform
Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform Integrating Clinical, Cognitive and Functional Assessments onto one device. Durham, NC—December 6, 2018—VeraSci, a global clinical technology and research services company,...
read moreNeuroCog Trials is now VeraSci
Durham, NC—October 12, 2018— NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery....
read moreLEADING ALZHEIMER’S DISEASE SCIENTIST JOINS NEUROCOG TRIALS
DURHAM, NC, July 9, 2018– Specializing in Alzheimer’s Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials...
read moreNeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease
Innovative technology answers the call for improved functional capacity measurements in cognitive disorders Durham, North Carolina, October 30, 2017 -- NeuroCog Trials, Inc. (NCT), the premier global cognition and clinical assessment consulting and technology company,...
read moreFORMER DIRECTOR GENERAL OF THE ITALIAN MEDICINES AGENCY (AIFA) DR. LUCA PANI JOINS NEUROCOG TRIALS
Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and...
read more